Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure

Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on... Key PointsQuestionWhat are the patterns of use and associated costs of sacubitril/valsartan and ivabradine for Medicare Part D and Medicaid? FindingsIn this US nationwide claims-based study, the number of Medicare beneficiaries prescribed sacubitril/valsartan increased from 35 423 to 90 606 (156% increase from 2016 to 2017). Medicare beneficiaries prescribed ivabradine increased from 15 856 to 23 213 (46% increase), the annual Medicare per-beneficiary spending on sacubitril/valsartan and ivabradine was $2512 and $2400, and parallel trends in use patterns and spending were observed among Medicaid beneficiaries. MeaningCurrent use of sacubitril/valsartan and ivabradine is increasing, but ongoing efforts are needed to promote high-value care, while improving affordability and access to established and emerging heart failure therapies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure

Loading next page...
 
/lp/american-medical-association/contemporary-patterns-of-medicare-and-medicaid-utilization-and-k6WmKVnEtb

References (14)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2019.4982
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat are the patterns of use and associated costs of sacubitril/valsartan and ivabradine for Medicare Part D and Medicaid? FindingsIn this US nationwide claims-based study, the number of Medicare beneficiaries prescribed sacubitril/valsartan increased from 35 423 to 90 606 (156% increase from 2016 to 2017). Medicare beneficiaries prescribed ivabradine increased from 15 856 to 23 213 (46% increase), the annual Medicare per-beneficiary spending on sacubitril/valsartan and ivabradine was $2512 and $2400, and parallel trends in use patterns and spending were observed among Medicaid beneficiaries. MeaningCurrent use of sacubitril/valsartan and ivabradine is increasing, but ongoing efforts are needed to promote high-value care, while improving affordability and access to established and emerging heart failure therapies.

Journal

JAMA CardiologyAmerican Medical Association

Published: Mar 18, 2020

There are no references for this article.